Ascendis Pharma A/S's (ASND) Overweight Rating Reiterated at Cantor Fitzgerald

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report)'s stock had its "overweight" rating reissued by equities researchers at Cantor Fitzgerald in a research report issued to clients and investors on Monday, Benzinga reports. They currently have a $173.00 price target on the biotechnology company's stock. Cantor Fitzgerald's price target indicates a potential upside of 13.83% from the stock's previous close.

Several other research analysts have also recently weighed in on the company. StockNews.com upgraded Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Monday, December 25th. Citigroup increased their price objective on Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a "buy" rating in a research report on Thursday, February 8th. Jefferies Financial Group initiated coverage on Ascendis Pharma A/S in a research report on Wednesday, December 20th. They set a "buy" rating and a $150.00 price objective on the stock. Wells Fargo & Company increased their price objective on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an "overweight" rating in a research report on Friday, March 15th. Finally, Wedbush increased their target price on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an "outperform" rating in a report on Thursday, February 8th. Four analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company's stock. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $174.14.

Ascendis Pharma A/S Stock Performance

ASND traded up $0.81 during trading hours on Monday, reaching $151.98. The company's stock had a trading volume of 330,468 shares, compared to its average volume of 387,348. Ascendis Pharma A/S has a 52 week low of $64.33 and a 52 week high of $161.00. The company's 50-day moving average is $145.99 and its 200-day moving average is $119.25. The firm has a market cap of $8.77 billion, a PE ratio of -16.43 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last posted its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating analysts' consensus estimates of ($2.15) by $0.49. The business had revenue of $148.62 million for the quarter, compared to analysts' expectations of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. Equities analysts anticipate that Ascendis Pharma A/S will post -4.16 earnings per share for the current fiscal year.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently bought and sold shares of ASND. Envestnet Asset Management Inc. boosted its stake in Ascendis Pharma A/S by 14.4% in the first quarter. Envestnet Asset Management Inc. now owns 2,246 shares of the biotechnology company's stock valued at $264,000 after buying an additional 282 shares in the last quarter. Rice Hall James & Associates LLC boosted its stake in Ascendis Pharma A/S by 35.1% in the first quarter. Rice Hall James & Associates LLC now owns 134,900 shares of the biotechnology company's stock valued at $15,832,000 after buying an additional 35,039 shares in the last quarter. Bank of New York Mellon Corp boosted its stake in Ascendis Pharma A/S by 20.5% in the first quarter. Bank of New York Mellon Corp now owns 289,344 shares of the biotechnology company's stock valued at $33,958,000 after buying an additional 49,298 shares in the last quarter. BlackRock Inc. boosted its stake in Ascendis Pharma A/S by 25.3% in the first quarter. BlackRock Inc. now owns 401,084 shares of the biotechnology company's stock valued at $47,070,000 after buying an additional 80,988 shares in the last quarter. Finally, Affinity Asset Advisors LLC acquired a new stake in Ascendis Pharma A/S in the first quarter valued at about $14,083,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.